Literature DB >> 34203263

Synthesis and Characterization of a "Clickable" PBR28 TSPO-Selective Ligand Derivative Suitable for the Functionalization of Biodegradable Polymer Nanoparticles.

Renato Auriemma1, Mattia Sponchioni1, Umberto Capasso Palmiero2, Giacomo Rossino3, Arianna Rossetti1, Andrea Marsala4, Simona Collina3, Alessandro Sacchetti1, Davide Moscatelli1, Marco Peviani4,5,6.   

Abstract

Reactive microgliosis is a pathological hallmark that accompanies neuronal demise in many neurodegenerative diseases, ranging from acute brain/spinal cord injuries to chronic diseases, such as amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD) and age-related dementia. One strategy to assess and monitor microgliosis is to use positron emission tomography (PET) by exploiting radioligands selective for the 18 kDa translocator protein (TSPO) which is highly upregulated in the brain in pathological conditions. Several TSPO ligands have been developed and validated, so far. Among these, PBR28 has been widely adopted for PET imaging at both preclinical and clinical levels, thanks to its high brain penetration and high selectivity. For this reason, PBR28 represents a good candidate for functionalization strategies, where this ligand could be exploited to drive selective targeting of TSPO-expressing cells. Since the PBR28 structure lacks functional moieties that could be exploited for derivatization, in this work we explored a synthetic pathway for the synthesis of a PBR28 derivative carrying an alkyne group (PBR-alkyne), enabling the fast conjugation of the ligand through azide-alkyne cycloaddition, also known as click-chemistry. As a proof of concept, we demonstrated in silico that the derivatized PBR28 ligand maintains the capability to fit into the TSPO binding pocked, and we successfully exploited PBR-alkyne to decorate zwitterionic biodegradable polymer nanoparticles (NPs) resulting in efficient internalization in cultured microglia-like cell lines.

Entities:  

Keywords:  TSPO; active targeting; click chemistry; microglia; neuroinflammation; polymer nanoparticles

Year:  2021        PMID: 34203263     DOI: 10.3390/nano11071693

Source DB:  PubMed          Journal:  Nanomaterials (Basel)        ISSN: 2079-4991            Impact factor:   5.076


  25 in total

Review 1.  Polymer nanoparticles for the intravenous delivery of anticancer drugs: the checkpoints on the road from the synthesis to clinical translation.

Authors:  R Ferrari; M Sponchioni; M Morbidelli; D Moscatelli
Journal:  Nanoscale       Date:  2018-12-13       Impact factor: 7.790

2.  A novel mitochondrially-targeted apocynin derivative prevents hyposmia and loss of motor function in the leucine-rich repeat kinase 2 (LRRK2(R1441G)) transgenic mouse model of Parkinson's disease.

Authors:  Brian P Dranka; Alison Gifford; Donna McAllister; Jacek Zielonka; Joy Joseph; Crystal L O'Hara; Cheryl L Stucky; Anumantha G Kanthasamy; Balaraman Kalyanaraman
Journal:  Neurosci Lett       Date:  2014-09-26       Impact factor: 3.046

3.  Zwitterionic Polyester-Based Nanoparticles with Tunable Size, Polymer Molecular Weight, and Degradation Time.

Authors:  Umberto Capasso Palmiero; Matteo Maraldi; Nicolò Manfredini; Davide Moscatelli
Journal:  Biomacromolecules       Date:  2018-03-15       Impact factor: 6.988

4.  A self-internalizing mitochondrial TSPO targeting imaging probe for fluorescence, MRI and EM.

Authors:  Lynn E Samuelson; Bernard M Anderson; Mingfeng Bai; Madeline J Dukes; Colette R Hunt; Jonathon D Casey; Zeqiu Han; Vassilios Papadopoulos; Darryl J Bornhop
Journal:  RSC Adv       Date:  2014-01-03       Impact factor: 3.361

Review 5.  Copper-catalyzed azide-alkyne cycloaddition (CuAAC) and beyond: new reactivity of copper(I) acetylides.

Authors:  Jason E Hein; Valery V Fokin
Journal:  Chem Soc Rev       Date:  2010-03-04       Impact factor: 54.564

6.  Translocator protein (TSPO) ligand-Ara-C (cytarabine) conjugates as a strategy to deliver antineoplastic drugs and to enhance drug clinical potential.

Authors:  Nunzio Denora; Valentino Laquintana; Adriana Trapani; Angela Lopedota; Andrea Latrofa; James M Gallo; Giuseppe Trapani
Journal:  Mol Pharm       Date:  2010-11-08       Impact factor: 4.939

7.  Strategy for improved [(11)C]DAA1106 radiosynthesis and in vivo peripheral benzodiazepine receptor imaging using microPET, evaluation of [(11)C]DAA1106.

Authors:  Katrin C Probst; David Izquierdo; Joseph L E Bird; Laurent Brichard; Dominic Franck; John R Davies; Tim D Fryer; Hugh K Richards; John C Clark; Anthony P Davenport; Peter L Weissberg; Elizabeth A Warburton
Journal:  Nucl Med Biol       Date:  2007-05       Impact factor: 2.408

Review 8.  Recent Progress in the Development of TSPO PET Ligands for Neuroinflammation Imaging in Neurological Diseases.

Authors:  Md Maqusood Alam; Jihye Lee; Sang-Yoon Lee
Journal:  Nucl Med Mol Imaging       Date:  2017-03-16

9.  Targeting Mitochondria in Tumor-Associated Macrophages using a Dendrimer-Conjugated TSPO Ligand that Stimulates Antitumor Signaling in Glioblastoma.

Authors:  Anjali Sharma; Kevin Liaw; Rishi Sharma; Ajit G Thomas; Barbara S Slusher; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Biomacromolecules       Date:  2020-08-31       Impact factor: 6.988

10.  Influence of alcoholism and cholesterol on TSPO binding in brain: PET [11C]PBR28 studies in humans and rodents.

Authors:  Sung Won Kim; Corinde E Wiers; Ryan Tyler; Ehsan Shokri-Kojori; Yeon Joo Jang; Amna Zehra; Clara Freeman; Veronica Ramirez; Elsa Lindgren; Gregg Miller; Elizabeth A Cabrera; Tyler Stodden; Min Guo; Şükrü B Demiral; Nancy Diazgranados; Luke Park; Jeih-San Liow; Victor Pike; Cheryl Morse; Leandro F Vendruscolo; Robert B Innis; George F Koob; Dardo Tomasi; Gene-Jack Wang; Nora D Volkow
Journal:  Neuropsychopharmacology       Date:  2018-05-03       Impact factor: 7.853

View more
  1 in total

Review 1.  Functionalization strategies of polymeric nanoparticles for drug delivery in Alzheimer's disease: Current trends and future perspectives.

Authors:  Livia La Barbera; Emanuele Mauri; Marcello D'Amelio; Manuele Gori
Journal:  Front Neurosci       Date:  2022-08-04       Impact factor: 5.152

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.